October 10th 2024
Various microorganisms, including molds and bacterial spores, were tested on stainless-steel coupons and demonstrated 2–6 log reductions with one-minute wet-contact times.
Using Tolerance Intervals for Evaluation of Uniformity of Dosage Units Data in Routine Batch Release
February 3rd 2024This article introduces that the basic technique for tolerance interval is implemented using the conventional range 85–115% LC where the proposed range in the PF is not taken into account.
Pooling of Batches for Stability Data Analysis
November 3rd 2023One of the main purposes of stability testing is to establish shelf life for these drug products. The goal of this paper is to create an Excel spreadsheet, which can be used for statistical testing of more than three stability batches for poolability.
In-Vitro Permeation Test Data Analysis with MS Excel as per FDA’s Guidance
July 3rd 2023FDA’s new guidance on in-vitro permeation test studies published in October 2022 gives technical and statistical requirements for conducting these tests to compare topical generic drugs with their reference products.
Total Analytical Error in Validation of Analytical Procedures of Pharmaceuticals
May 2nd 2023This paper demonstrates how assay data sets of a formulated liquid product, drug substance, and an impurity, obtained from combined accuracy-precision studies, are evaluated to calculate statistical intervals (prediction and tolerance intervals) and to graphically display the total analytical error (TAE) to account for the systematic and random errors.
Supplementary Handwashing Techniques to Improve Hand Hygiene
February 3rd 2023A fluorescence test method was used to visually evaluate handwashing efficacy. Difficult-to-clean areas on skin such as skin folds and webbing between fingers were identified; specific washing techniques to address problem areas are proposed.
The Value of Primary Working Standards in Pharmaceutical Quality Control
September 3rd 2022It is argued that orthogonal quantitative methods can be used to establish primary working standards. An example details how to calculate the expanded measurement uncertainty (U) for the certified assay value by considering two orthogonal assay methods.
A Novel Cell Lysis Method to Improve the Viral Vector Manufacturing Process
Researchers demonstrated a new cell lysis method using a novel solution to improve viral vector production.
Grouping Products and Equipment for a Worst-Case Cleaning Validation Study
August 3rd 2021A robust selection of which product(s) and equipment to validate for cleaning is the cornerstone of a successful cleaning validation program. A strategy for selection of products and equipment for cleaning validation is presented.
Comparing Methods for Determining Out-of-Trend Stability Test Results
April 3rd 2021This article describes in detail how simulation was used to compare the statistical techniques used to determine out-of-trend (OOT), which is crucial to avoiding out-of-specification (OOS) events for drug substances and products.
Using Modified QbD to Develop a Novel Pediatric Formulation of Ezogabine
March 3rd 2021The epilepsy treatment, Potiga, has been used off-label to treat specific types of epilepsy in some children. However, it has never been formally evaluated in pediatric clinical trials. Using a modified QbD approach, the authors have developed a granular formulation suitable for use in clinical trials involving infants and children.
ECHA’s Microplastics Use Restriction—Impact on Pharmaceuticals
January 3rd 2021To restrict the use of intentionally added microplastics, the European Chemicals Agency has proposed a restriction dossier that describes various measures aimed at minimizing the use of microplastics in various industrial segments, including pharmaceuticals. In this paper, the authors discuss these restrictions.
Development of a Validated Method of Testing for NDMA in Ranitidine
October 3rd 2020This article describes a validated method, using liquid chromatography/mass spectrometry, for detecting the carcinogenic impurity NDMA (N-nitrosodimethylamine) in ranitidine that meets and exceeds FDA’s limit of detection and limit of quantitation requirements.
Assessment of Nanosuspension Formulation for Intranasal Administration
Research suggests that intranasal nanosuspensions offer a promising way to formulate and deliver drugs that are poorly soluble in water to patients with chronic conditions.